MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc.(“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the ...